NY-ESO-1-Specific TCR Lentivirus (Clone 1G4)
The human NY-ESO-1-specific T Cell Receptor (TCR) lentiviruses (clone 1G4) are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce cells with a human TCR (clone 1G4) that specifically recognizes antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1), and in which the TCR α chain and β chain are linked by P2A (Figure 1). The lentiviruses also transduce a puromycin selection gene.
Figure 1. (A) Schematic of the lenti-vector used to generate the NY-ESO-1-specific TCR lentivirus and (B) Construct diagram showing expressed components of the NY-ESO-1-specific TCR. TRAV and TRAC correspond to the TCR alpha chain variable and constant regions, respectively, whereas TRBV and TRBC correspond to the TCR beta chain variable and constant regions.
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2C | BPS Bioscience #79592 |
Assay Medium 2D | BPS Bioscience #78755 |
TCR KO NFAT Luciferase Reporter Jurkat Cell Line | BPS Bioscience #78556 |
CD8+ TCR KO NFAT Luciferase Reporter Jurkat Cell Line | BPS Bioscience #78757 |
T2 Cell Line | ATCC #CRL-1992 |
A375 Cells | ATCC #CRL-1619 |
NY-ESO-1 (157-165) Peptide | BPS Bioscience #78758 |
MART-1 (Leu26-35, Leu27) Peptide | BPS Bioscience #78760 |
APC MHC I Dextramer (HLA-A*02:01 SLLMWITQV) |
Immudex #WB03247 |
PE anti-human α/β T Cell Receptor Antibody | BioLegend #306707 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Polybrene | Millipore Sigma #TR-1003-G |
The lentiviruses were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
NY-ESO-1 (New York esophageal squamous cell carcinoma 1, also known as Cancer/testis antigen 1, or CTAG1B), is an important tumorigenic marker present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but is re-expressed in multiple myeloma, non-small cell lung carcinoma, and breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors.